SEC Tracker
Get the app

BridgeBio Pharma BBIO

Kumar Haldea Revocable Trust U/A DTD 12/19/2018 (Director) plans to sell 600,000 BBIO shares, about $22M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Jan 28, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Conversion Management Incentive Units
  4. 10b5-1 plan adopted: Mar 22, 2024

All of Kumar Haldea Revocable Trust U/A DTD 12/19/2018's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 326,932 shares at $36.29 on Jan 28, 2025 · Form 4
  • Sold 269,068 shares at $36.34 on Jan 29, 2025 · Form 4
  • Sold 4,000 shares at $36.82 on Jan 29, 2025 · Form 4
  • Sold 76 shares at $36.56 on Feb 19, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  3. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  4. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  5. Repligen RGEN public float $6.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.